Immunic Inc   (IMUX)
Other Ticker:  

Immunic Inc

Business Description

Immunic Inc is a clinical-stage biopharmaceutical company that is focused on developing innovative therapies for the treatment of various immune-mediated diseases. The company was founded in 2016 and is headquartered in New York, with additional offices in Munich, Germany.

The primary goal of Immunic is to develop small molecule drugs that modulate the immune system to target specific diseases. These diseases may include autoimmune disorders, chronic inflammation, and cancer. The company*s approach is centered around the discovery and development of selective oral immunometabolic drugs.

Immunic has a diverse pipeline of drug candidates targeting different immune-mediated diseases. One of its lead drug candidates is IMU-838, which is being developed for the treatment of multiple sclerosis (MS), ulcerative colitis (UC), and Crohn*s disease (CD). IMU-838 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme involved in the de novo pyrimidine biosynthesis pathway. By inhibiting this pathway, IMU-838 has the potential to reduce inflammation and control the immune response.

Another drug candidate in Immunic*s pipeline is IMU-935, which targets the treatment of Parkinson*s disease. IMU-935 is a small molecule inhibitor of the enzyme monoacylglycerol lipase (MAGL), which is involved in the metabolism of endocannabinoids. By modulating the endocannabinoid system, IMU-935 aims to reduce neuroinflammation and protect dopaminergic neurons in Parkinson*s disease.

In addition to its lead candidates, Immunic is also developing IMU-856, which is being explored for the treatment of primary sclerosing cholangitis (PSC), a rare autoimmune liver disease. IMU-856 is a selective antagonist of ROR?t, a nuclear receptor specifically expressed in immune cells that play a critical role in autoimmune diseases.

The company applies a comprehensive approach to drug development, encompassing preclinical research, clinical trials, regulatory affairs, and commercialization strategies. Immunic*s team consists of experienced scientists, clinicians, and industry professionals who collaborate to bring novel therapies to patients in need.

Immunic is also actively engaged in strategic partnerships and collaborations to accelerate drug development and enhance its capabilities. The company has collaborations with various academic institutions and has received funding from government grants and venture capital investments.

Overall, Immunic Inc is a biopharmaceutical company focused on developing innovative therapies for immune-mediated diseases. With a robust pipeline and a dedicated team, the company aims to provide effective treatment options for patients suffering from autoimmune disorders and chronic inflammation.

View Company Supplier View Company Competition View Company Customers


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com